Asian Growth Companies With High Insider Ownership In November 2025

As global markets face volatility, particularly in the technology sector, Asian markets have shown resilience with Chinese indices reaching new highs amid easing trade tensions. In this environment, growth companies with high insider ownership can be appealing as they often indicate strong confidence from those who know the business best and may offer stability amidst broader market fluctuations.

Name

Insider Ownership

Earnings Growth

Streamax Technology (SZSE:002970)

32.5%

33.1%

Seers Technology (KOSDAQ:A458870)

33.9%

84.6%

Novoray (SHSE:688300)

23.6%

31.4%

M31 Technology (TPEX:6643)

26.3%

117.3%

Loadstar Capital K.K (TSE:3482)

31%

23.6%

Laopu Gold (SEHK:6181)

34.8%

34.3%

J&V Energy Technology (TWSE:6869)

17.5%

24.9%

Gold Circuit Electronics (TWSE:2368)

31.4%

35.2%

Fulin Precision (SZSE:300432)

11.6%

55.2%

Ascentage Pharma Group International (SEHK:6855)

12.8%

56.2%

Click here to see the full list of 627 stocks from our Fast Growing Asian Companies With High Insider Ownership screener.

We’ll examine a selection from our screener results.

Simply Wall St Growth Rating: ★★★★★☆

Overview: Beijing Fourth Paradigm Technology Co., Ltd. is an investment holding company offering platform-centric artificial intelligence solutions in China, with a market cap of HK$27.53 billion.

Operations: The company’s revenue is primarily derived from three segments: Sagegpt Aigs Services (CN¥505.70 million), 4ParadigmSage AI Platform (CN¥4.57 billion), and Shift Intelligent Solutions (CN¥940.30 million).

Insider Ownership: 20.5%

Earnings Growth Forecast: 110.3% p.a.

Beijing Fourth Paradigm Technology has shown significant revenue growth, with a 26.7% annual forecast surpassing the Hong Kong market’s average. Recent partnerships, like its strategic alliance with Solowin Holdings for blockchain compliance solutions, highlight its innovative edge. Despite a net loss reduction to CNY 66.97 million and a follow-on equity offering raising HK$1.31 billion, insider ownership remains high without substantial recent buying or selling activity reported in the last three months.

SEHK:6682 Ownership Breakdown as at Nov 2025

Simply Wall St Growth Rating: ★★★★★☆

Overview: InnoCare Pharma Limited is a biopharmaceutical company focused on discovering, developing, and commercializing drugs for cancer and autoimmune diseases in China, with a market cap of HK$28.93 billion.

Continue Reading